Radiotherapy dosing for locally advanced non-small cell lung carcinoma: "MTD" or "ALARA"?

10Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

Abstract

Locally advanced non-small cell lung cancer (LA-NSCLC) is typically treated with thoracic radiotherapy, often in combination with cytotoxic chemotherapy. Despite tremendous advances in the evaluation, treatment techniques, and supportive care measures provided to LA-NSCLC patients, local disease progression and distant metastases frequently develop following definitive therapy. A recent landmark randomized trial demonstrated that radiotherapy dose escalation may reduce survival rates, highlighting our poor understanding of the effects of thoracic radiotherapy for LA-NSCLC. Here, we present rationale for further studies of radiotherapy dose escalation as well as arguments for exploring relatively low radiotherapy doses for LA-NSCLC.

Cite

CITATION STYLE

APA

Ohri, N. (2017, September 21). Radiotherapy dosing for locally advanced non-small cell lung carcinoma: “MTD” or “ALARA”? Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2017.00205

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free